Earnings Summary

G1 Therapeutics Inc’s revenue jumped 45.1% since last year same period to $14.87Mn in the Q4 2023. On a quarterly growth basis, G1 Therapeutics Inc has generated 20.92% jump in its revenue since last 3-months.

G1 Therapeutics Inc’s net profit jumped 67.67% since last year same period to $-10.88Mn in the Q4 2023. On a quarterly growth basis, G1 Therapeutics Inc has generated 40.24% jump in its net profits since last 3-months.

G1 Therapeutics Inc’s net profit margin jumped 77.72% since last year same period to -73.14% in the Q4 2023. On a quarterly growth basis, G1 Therapeutics Inc has generated 50.58% jump in its net profit margins since last 3-months.

G1 Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 25% jump from last quarter’s estimates.

G1 Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.21.

G1 Therapeutics Inc’s earning per share (EPS) jumped 71.23% since last year same period to -0.21 in the Q4 2023. This indicates that the G1 Therapeutics Inc has generated 71.23% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. G1 Therapeutics Inc’s return on assets (ROA) stands at -0.16.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. G1 Therapeutics Inc’s return on equity (ROE) stands at -0.92.